Benefits
Mast Cell Stabilization
Luteolin is a potent inhibitor of mast cell degranulation — mast cells release histamine, tryptase, and inflammatory mediators in allergies and mast cell activation syndrome (MCAS). Luteolin is commonly used in mast cell and allergy support protocols, often combined with quercetin; supporting human evidence is largely open-label/observational.
Neuroinflammation Reduction
Luteolin reduces microglial activation and pro-inflammatory cytokines in animal models, consistent with supporting a healthy neuroinflammatory response in the brain. Evidence to date is from animal models; human data are preliminary.
Cardiovascular Anti-Atherosclerotic Effects
May help reduce LDL oxidation, vascular inflammation, and adhesion-molecule expression in mechanistic and animal studies, supporting cardiovascular health. Modest cholesterol effects. Evidence is largely mechanistic and preclinical.
Senolytic Activity (Adjunctive)
Identified along with fisetin in Mayo Clinic flavonoid screening as having senolytic activity, though less potent than fisetin. Component of multi-flavonoid longevity stacks.
Mechanism of action
Mast Cell Stabilization
Luteolin inhibits mast cell degranulation by stabilizing mast cell membranes and inhibiting calcium-dependent degranulation pathways. Reduces histamine, tryptase, and cytokine release. Foundational mechanism for allergy/MCAS application.
NF-κB Pathway Inhibition
Inhibits NF-κB activation — reducing pro-inflammatory gene expression (TNF-alpha, IL-6, IL-1β, COX-2, iNOS). Broad anti-inflammatory profile.
Microglial Modulation (Brain)
Reduces activated microglia (the brain's immune cells) — relevant for neuroinflammation in chronic neurological conditions. Crosses blood-brain barrier.
Histamine N-Methyltransferase Effects
Modest inhibition of histamine breakdown enzymes balanced against mast cell stabilization — net effect depends on context. Generally anti-allergic clinically.
Clinical trials
Open-label trial of luteolin formulation (with quercetin and rutin in liposomal form) in children with ASD over 26 weeks.
37 children with ASD.
Open-label improvements in adaptive behaviors, communication, social interaction, and GI symptoms. Critical caveats: open-label with no placebo control, and it tested a luteolin-CONTAINING formulation (with quercetin and rutin), not luteolin alone. Theoretical mechanism (neuroinflammation reduction) has gained interest.
Multiple papers and case series by Theoharides et al. on luteolin as mast cell stabilizer for MCAS, chronic urticaria, related conditions.
MCAS patients, chronic urticaria patients.
Modest symptom improvements in mast cell-related conditions. Open-label/observational primarily; rigorous clinical trials limited. Foundational supplement in functional medicine MCAS protocols.